Effect of pregnenolone carbonitrile, promethazine and antipyrine pretreatment on antipyrine metabolite formation in rats

References

• Alvares A. P., Kappas A. Hetereogeneity of cytochrome P450's induced by polychlorinated biphenyls. Journal of Biological Chemistry 1977; 252: 6373–6378
   PubMed Web of Science ®Google Scholar
• Benford D. J., Bridges J. W., Boobis A. R., Kahn G. C., Brodie M. J., Davies D. S. The selective activation of cytochrome P-450 dependent microsomal hydroxylases in human and rat liver microsomes. Biochemical Pharmacology 1981; 30: 1702–1703
   PubMed Web of Science ®Google Scholar
• Boobis A. R., Brodie M. J., Kahn G. C., Toverud E. L., Blair I. A., Murray S., Davies D. S. Comparison of the in vivo rates of formation of the three main oxidative metabolites of antipyrine in man. British Journal of Clinical Pharmacology 1981; 13: 771–777
   Google Scholar
• Böttcher J., Bässman H., Schüppel R. Quantitation and urinary pattern of 4,4′-dihydroxy antipyrine, 4-hydroxyantipyrine and 3-hydroxymethylantipyrine as main metabolites of antipyrine in man and rat. Journal of Pharmacy and Pharmacology 1982; 34: 168–175
   PubMed Web of Science ®Google Scholar
• Böttcher J., Bässman H., Schüppel R. Quantitation of norantipyrine sulphate and norantypyrine glucuronide as major metabolites of antipyrine in man and rat. Journal of Pharmacy and Pharmacology 1984; 36: 391–398
   PubMedGoogle Scholar
• Breckenridge A., Orme M. L'E., Thorgiersson S., Davies D. S., Brooks R. V. Drug interactions with warfarin. The effect of dichloralphenazone, phenazone and chloralhydrate. Clinical Science 1971; 40: 351–364
   PubMed Web of Science ®Google Scholar
• Danhof M., Krom D. P., Breimep D. D. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methyicholanthrene treatment. Xenobiotica 1979; 9: 695–702
   PubMed Web of Science ®Google Scholar
• Danhof M., Verbeek R. M. A., Van Boxtel C. J., Boejinga J. K., Breimer D. D. Differential effects of enzyme induction on antipyrine metabolite formation. British Journal of Clinical Pharmacology 1982; 13: 379–386
   PubMed Web of Science ®Google Scholar
• Elshourbagy N. A., Guzelian P. S. Separation, purification and characterisation of a novel form of hepatic cytochrome p-450 from rats treated with pregnenolone 16-α-carbonitrile. Journal of Biological Chemistry 1980; 255: 1279–1285
   PubMed Web of Science ®Google Scholar
• Hall S. T., Houston J. B., Shaw P. N. Antipyrine metabolite kinetics in pregnenolone 16-α-carbonitrile treated rats. British Journal of Pharmacology 1983; 80: 479P
   Google Scholar
• Houston J. B. Drug metabolite kinetics. Pharmacology and Therapeutics 1981; 15: 521–552
   PubMed Web of Science ®Google Scholar
• Houston J. B., Lockwood G. F., Taylor G. Aminopyrine demethylation kinetics: use of metabolite exhalation rates as an index of enhanced mixed function oxidase activity in vivo. Drug Metabolism and Disposition 1981; 9: 449–455
   PubMed Web of Science ®Google Scholar
• Kahn G. C., Boobis A. R., Murray S., Davies D. S. Differential effects of 3-methylcholanthrene and phenobarbitone treatmenc on the oxidaiive metabolism of antipyrine in vitro by microsomal fractions of rat liver. Xenobiotica 1982; 12: 509–516
   PubMed Web of Science ®Google Scholar
• Ly A. Y. H., Somogyi A., West S., Kuntzman R., Conney A. H. Pregnenolone-16α-carbonitrile-new type of inducer of drug metabolising enzymes. Archives of Biochemistry and Biophysics 1972; 152: 457–462
   PubMedGoogle Scholar
• Ohnhaus E. E., Park B. K. Measurement of urinary 6 β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme inducing capacity of antipyrine, phenobarbitone and rifampicin. European Journal of Clinical Pharmacology 1979; 15: 139–149
   PubMed Web of Science ®Google Scholar
• Rhodes J. C., Houston J. B. Antipyrine metabolite kinetics in phenobarbital and β-naphthoflavone induced rats. Drug Metabolism and Disposition 1983a; 11: 131–136
   PubMed Web of Science ®Google Scholar
• Rhodes J. C., Houston J. B. Antipyrine metabolite kinetics in rats: studies on dose and time dependence. Biopharmaceutics and Drug Disposition 1983b; 4: 125–135
   PubMed Web of Science ®Google Scholar
• Rhodes J. C., Hall S. T., Houston J. B. Inhibition of antipyrine metabolite formation in rats in vivo. Xenobiotica 1984; 14: 677–686
   PubMed Web of Science ®Google Scholar
• Ryan D. E., Thomas P. E., Levin W. Properties of purified liver microsomal cytochrome P-450 from rats treated with the polychlorinated biphenyl mixture Aroclor 1254. Molecular Pharmacology 1977; 13: 521–532
   PubMed Web of Science ®Google Scholar
• Shaw P. N., Houston J. B., Rowland M., Hopkins K., Thiercelin J. F., Morselli P. L. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. British Journal of Clinical Pharmacology 1985; 20: 611–618
   PubMed Web of Science ®Google Scholar
• Stevenson I. H. Factors influencing antipyrine elimination. British Journal of Clinical Pharmacology 1977; 4: 261–265
   PubMed Web of Science ®Google Scholar
• Taylor G., Houston J. B., Elcombe C. R. Effect of promethazine and isosafrole on rat hepatic microsomal mono-oxygenase activity—comparison with classic inducers, phenobarbitone and β-naphthoflavone. Xenobiotica 1985; 15: 243–249
   PubMed Web of Science ®Google Scholar
• Teunissen M. W. E., Joeres R. P., Vermeulen N. P. E., Breimer D. D. Influence of 9-hydroxyellipticine and 3-methyl-cholanthrene treatment on antipyrine metabolite formation in rats in vivo. Xenobiotica 1983; 13: 223–231
   PubMed Web of Science ®Google Scholar
• Teunissex M. W. E., Kleinbloesem C. H., De Leede L. G. J., Breimer D. D. Influence of cirnetidine on steady-state concentration and metabolite formation from antipyrine infused with a rectal osmotic pump. European Journal of Clinical Pharmacology 1985; 28: 681–684
   PubMedGoogle Scholar
• Tovehud E. L., Boobis A. R., Brodie M. J., Murray S., Bennett P. N., Wkitmarsh V., Davies D. S. Differential induction of antipyrine metabolism by rifampicin. European Journal of Clinical Pharmacology 1981; 21: 155–160
   PubMedGoogle Scholar
• Van DEN Broek J. M., Teunissen M. W. E., Breimer D. D. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig. Drug Metabolism and Disposition 1981; 9: 541–544
   PubMed Web of Science ®Google Scholar
• Vesell E. S. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clinical Pharmacology and Therapeutics 1971; 26: 275–286
   Google Scholar